Immutep Secures A$30M Upfront Payment in Major Licensing Deal, Extends Cash Runway

summarizeSummary

Immutep announced a strategic collaboration with Dr. Reddy's for its lead immunotherapy, eftilagimod alfa, securing an A$30.2 million upfront payment and significantly extending its cash runway into Q2 CY2027, alongside multiple positive clinical and regulatory updates.

check_boxKey Events

• Strategic Licensing Agreement with Dr. Reddy's

  Immutep entered into an exclusive licensing agreement with Dr. Reddy's for eftilagimod alfa in key international markets, receiving an upfront payment of A$30.2 million (USD 20 million) and eligible for up to A$528.4 million (USD 349.5 million) in potential milestones, plus royalties.

• Extended Cash Runway

  The upfront payment from Dr. Reddy's, combined with existing cash and a A$30 million vendor payment deferral, boosts Immutep's pro-forma cash balance to A$129.3 million, extending its financial runway well into Q2 CY2027.

• Positive Clinical Trial Progress for Eftilagimod Alfa

  The company reported strong operational progress for the TACTI-004 Phase III trial in NSCLC, positive data from INSIGHT-003 (NSCLC) and EFTISARC-NEO (soft tissue sarcoma), and encouraging results from AIPAC-003 (metastatic breast cancer).

• FDA Agreement on Optimal Dosing

  Immutep received positive feedback from the FDA, agreeing on 30 mg as the optimal biological dose for eftilagimod alfa, providing strategic clarity for ongoing and future clinical development.

auto_awesomeAnalysis

This 6-K filing is highly significant due to the strategic collaboration with Dr. Reddy's, which includes a substantial A$30.2 million upfront payment. This non-dilutive capital injection, combined with a vendor payment deferral, significantly strengthens Immutep's financial position, extending its cash runway well into Q2 CY2027. This de-risks the company's operations and provides crucial funding for ongoing clinical development. Furthermore, the filing details multiple positive clinical and regulatory updates for its lead asset, eftilagimod alfa, across various cancer indications, and promising early-stage data for IMP761, reinforcing the pipeline's potential and validating the company's therapeutic approach.